Merck Pipeline

As of August 3, 2015

MERCK
Be well

Merck Pipeline as of August 3, 2015

Phase 2	Phase 2	Phase 3	Phase 3	Phase 3
Alzheimer's Disease **MK-7622**	Contraception, Next Generation Ring **MK-8342B**	Allergy, House Dust Mite **MK-8237**[1,2]	Diabetes Mellitus **omarigliptin, MK-3102**	HIV **doravirine, MK-1439**
Asthma **MK-1029**	▶ Diabetes Mellitus **MK-8521**	Alzheimer's Disease **verubecestat, MK-8931**	Diabetes Mellitus **ertugliflozin, MK-8835** [1]	HABP/VABP[3] bacterial pneumonia **ZERBAXA™, MK-7625A**
Bacterial Infection **relebactam, MK-7655**	Heart Failure **vericiguat, MK-1242**[1]	Atherosclerosis **anacetrapib, MK-0859**	Diabetes Mellitus **MK-1293** [1]	HABP/VABP[3] bacterial pneumonia **SIVEXTRO®, MK-1986**
▶ Breast Cancer **KEYTRUDA®, MK-3475**	Hepatitis C **MK-3682/ MK-8742(elbasvir)/ MK-5172(grazoprevir)**	Bladder Cancer **KEYTRUDA® MK-3475**	Ebola Vaccine **V920**	Non-Small Cell Lung Cancer **KEYTRUDA®, MK-3475 (EU)**
Cancer **MK-2206**	Hepatitis C **MK-3682/MK-8408/ MK-5172(grazoprevir)**	*Clostridium difficile* Infection **actoxumab/bezlotoxumab, MK-3415A**	▶ Gastric Cancer **KEYTRUDA® MK-3475**	Osteoporosis **odanacatib, MK-0822**
Cancer **MK-8628**	▶ Hodgkin Lymphoma **KEYTRUDA®, MK-3475**	*Clostridium difficile* Infection **surotomycin, MK-4261**	Head and Neck Cancer **KEYTRUDA® MK-3475**	
	Pneumoconjugate Vaccine **V114**	CMV Prophylaxis in Transplant Patients, **letermovir, MK-8228**	Herpes Zoster **inactivated VZV vaccine, V212**	

1. Being developed in a collaboration.
2. North American rights.
3. HABP - Hospital-acquired bacterial pneumonia/ VABP - ventilator-associated bacterial pneumonia

▶ Moved forward since last pipeline update.

MERCK Be well

Merck Pipeline as of August 3, 2015

New Molecular Entities Under Review	New Molecular Entities Under Review	New Molecular Entities Approvals[2]	New Molecular Entities Approvals[2]	New Indications /Formulations[1] Approvals[2]
Diabetes Mellitus **omarigliptin** **MK-3102 (Japan)**	Neuromuscular Blockade Reversal **BRIDION®** **MK-8616 (US)[4]**	Allergy **GRASTEK® [6]** **MK-7243 (US)**	▶ HPV-Related Cancers **GARDASIL®9** **V503 (US/EU)**	Antifungal **NOXAFIL®** **MK-5592** **(solid oral tablet) (US/EU)**
Complicated intra-abdominal infections (cIAI) & complicated urinary tract infections (cUTI) **ZERBAXA™** **MK-7625A (EU)[3]**	▶ Non-Small Cell Lung Cancer **KEYTRUDA®** **MK-3475 (US)**	Allergy **RAGWITEK™ [6]** **MK-3641 (US)**	Insomnia **BELSOMRA®** **MK-4305** **(US, Japan)**	Antifungal **NOXAFIL®** **MK-5592 (IV)** **(US/EU)**
▶ Hepatitis C **grazoprevir/elbasvir,** **MK-5172A (US/EU)**	Pediatric Hexavalent Combination Vaccine **V419 (US/EU)[5]**	Acute bacterial skin & skin structure infections (ABSSSI) **SIVEXTRO®** **MK-1986 (EU)**	▶ Melanoma **KEYTRUDA®** **MK-3475** **(US/EU)**	HIV **DUTREBIS™** **MK-0518B (EU)**
		Hepatitis C **VANIHEP®** **MK-7009 (Japan)**	Thrombosis **ZONTIVITY®** **MK-5348** **(US/EU)**	

1. New indications/formulation updates are solely intended to provide general information regarding Merck projects in development and, for this reason, the information is not represented to be complete.
2. Approvals obtained within the last 12 months.
3. In July 2015, the CHMP of the EMA issued a positive opinion recommending approval of ZERBAXA; the EC has not yet adopted the opinion.
4. In April 2015, Merck received a CRL for the resubmission of the NDA for Bridion (MK-8616). In June 2015, the FDA accepted Merck's resubmission in response to the CRL.
5. V419 is being developed in partnership with Sanofi Pasteur and if approved, will be co-promoted via a US partnership and marketed via the SPMSD joint venture in Europe.
6. North American rights.

▶ Moved forward since last pipeline update.

MERCK
Be well

Forward-Looking Statement

This news release of Merck & Co., Inc., Kenilworth, NJ, USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2014 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

No Duty to Update

The information contained in the presentation set forth below was current as of August 3, 2015. While this presentation remains on the Company's website the Company assumes no duty to update the information to reflect subsequent developments. Consequently, the Company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after August 3, 2015.

The chart reflects the Merck research pipeline as of August 3, 2015.

Candidates shown in Phase III include specific products. Candidates shown in Phase II include the most advanced compound with a specific mechanism in a given therapeutic area. Phase I candidates are not shown.